Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Ina Rhee, M.D., Ph.D.
Genentech, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
42 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
St Leonards, New South Wales, Australia
- Facility name not stated
Herston, Queensland, Australia
- Facility name not stated
Woodville South, South Australia, Australia
- Facility name not stated
Brno, Czechia
- Facility name not stated
Ostrava - Poruba, Czechia
- Facility name not stated
Le Mans, France
- Facility name not stated
Lyon, France
- Facility name not stated
Marseille, France
- Facility name not stated
Marseille, France
- Facility name not stated
Paris, France
- Facility name not stated
Saint-Herblain, France
- Facility name not stated
Toulouse, France
- Facility name not stated
Essen, Germany
- Facility name not stated
Gauting, Germany
- Facility name not stated
Großhansdorf, Germany
- Facility name not stated
Halle, Germany
- Facility name not stated
Budapest, Hungary
- Facility name not stated
Budapest, Hungary
- Facility name not stated
Székesfehérvár, Hungary
- Facility name not stated
Tatabánya, Hungary
- Facility name not stated
Bydgoszcz, Poland
- Facility name not stated
Gdansk, Poland
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
Hot Springs, Arkansas, United States
- Facility name not stated
Santa Monica, California, United States
- Facility name not stated
Orlando, Florida, United States
- Facility name not stated
Port Saint Lucie, Florida, United States
- Facility name not stated
St. Petersburg, Florida, United States
- Facility name not stated
Tampa, Florida, United States
- Facility name not stated
Marietta, Georgia, United States
- Facility name not stated
Indianapolis, Indiana, United States
- Facility name not stated
Wichita, Kansas, United States
- Facility name not stated
Burnsville, Minnesota, United States
- Facility name not stated
Las Vegas, Nevada, United States
- Facility name not stated
Albany, New York, United States
- Facility name not stated
Columbus, Ohio, United States
- Facility name not stated
Portland, Oregon, United States
- Facility name not stated
Hershey, Pennsylvania, United States
- Facility name not stated
Nashville, Tennessee, United States
- Facility name not stated
Austin, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2011
- Primary completion
- 28 Feb 2013
- Completion
- —
- Last update posted
- 2 Nov 2016
- Registered enrollment
- 104
- Registry id
- NCT01366131
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.